Omalizumab (Xolair) maintained efficacy for chronic rhinosinusitis with nasal polyps, a researcher reported.
In an open-label extension study of two, 24-week clinical trials, omalizumab was associated with significant improvements in nasal polyp scores (mean change -0.97, 95% CI -1.25 to -0.69), nasal congestion scores (mean change -0.99, 95% CI -1.14 to -0.83), and Sino-Nasal Outcome Test (SNOT) scores (mean change -22.39, 95% CI -25.39 to -19.40) through 1 year, according to Philippe Gevaert, MD, PhD, of Ghent University in Belgium.
“Scores worsened following omalizumab withdrawal, but remained above pre-treatment levels at week 76,” Gevaert said during a presentation at the American College of Allergy, Asthma & Immunology virtual meeting.
Omalizumab is thought to bind to free local immunoglobulin E (IgE), reducing inflammation that occurs with nasal polyps, Gevaert said.
Currently, dupilumab (Dupixent) is the only FDA-approved therapy to treat chronic rhinosinusitis with nasal polyps, and omalizumab is approved for treating moderate to severe persistent asthma.
The FDA did accept a supplemental biologics license application for this indication in 2019, but the application has not yet been reviewed due to the COVID-19 pandemic, noted Joseph Han, MD, of the Eastern Virginia Medical School in Norfolk, during a discussion of the findings.
Han added that he suspects “we may be able to find a decision soon.”
The European Commission approved omalizumab as an add-on therapy to intranasal corticosteroids for treating severe and persistent chronic rhinosinusitis with nasal polyps in August 2020.
Patients on either omalizumab or placebo in the original POLYP 1 and POLYP 2 studies were enrolled in this extension trial after 24 weeks. All patients then received 28 weeks of treatment followed by another 24 weeks of follow-up, during which they were only receiving background nasal spray.
The most common adverse event during the treatment period was nasopharyngitis, which occurred in 4.8% of patients. Otherwise the drug was well-tolerated, Gevaert said.
Overall, 95.6% of patients completed the extension treatment period and 92.8% completed the follow-up. Patients originally on placebo showed a similar treatment response to patients who continued omalizumab treatment from the previous study.
Many patients in the trial had surgery before entering the trial, but there was no difference in any of the outcomes when comparing patients with or without surgery, Gevaert said.
“In order to be included in the trial, you had to have a combined nasal polyp score of at least 5,” Gevaert said. “So although patients had surgery before, there was a regrowth of polyp large enough for them to be included in the trial.”
Disclosures
Gevaert disclosed relevant relationships with ALK, Argenx, AstraZeneca, Genentech, Hal Allergy, Novartis, Regeneron, Roche, Sanofi, and Stallergenes.
Co-authors disclosed multiple relevant relationships with industry including Genentech.
Related Post
Apr
Top 10 Health Benefits of Reflexology
Did you realize reflexology is a back rub method that can be followed back to Old Egypt? Here of back rub, the strain is applied in unambiguous regions or zones in the hands and feet that associate to various pieces.
Read MoreMar
The Health Benefits of Deep Breathing (and 4 Easy Techniques!)
Breathing is a characteristic and compulsory activity that occurs for our bodies to take in and discharge air. A necessary activity assists our bodies with working through day to day existence. Breathing assists our respiratory framework with moving oxygen in.
Read MoreMar
10 Yoga Poses to Boost the Immune System
As the days get more limited and temperatures decrease, we might have seen our schedules are advising us that the Christmas season is quick drawing nearer. That additionally implies that cold and influenza season is back! Yet again sadly for.
Read MoreMar
7 Health Benefits of Attending Concerts
Music resembles an embrace for your spirit. Music is quite possibly of the best gift we have on this planet. It assists us with communicating our feelings, it interfaces with others, and it could actually help us unwind and ease.
Read More